Whether you’ve been struggling with stubborn weight for years or you’re just curious about prescription options, the landscape of weight loss medication can be hard to navigate — but clinical trials show drugs like semaglutide can lead to 15% body weight loss over 68 weeks. This guide walks through the most effective medications, eligibility in Ireland and the UK, expected results, side effects, and what to watch out for, so you can have an informed conversation with your GP.

4 related posts

FDA-approved weight-loss drugs: 5 (per Mayo Clinic) · Average weight loss with semaglutide: 15% over 68 weeks · Monthly Ozempic cost (US, no insurance): ~$900

Quick snapshot

1Top Weight Loss Medications
  • Ozempic (semaglutide) – GLP-1 agonist (NHS)
  • Mounjaro (tirzepatide) – GIP/GLP-1 agonist (HSE)
  • Saxenda (liraglutide) – GLP-1 agonist (HSE)
  • Contrave (bupropion-naltrexone) – combination tablet (FDA-approved per Mayo Clinic)
2Eligibility in Ireland
  • BMI ≥30 or ≥27 with weight-related condition (HSE)
  • HSE approval required for coverage (HSE)
  • Not for everyone; see your GP (HSE)
3Expected Weight Loss
  • Average 1–2 lbs per week
  • 15% body weight over 68 weeks
  • Results vary by adherence
4Cost and Insurance
  • Ozempic ~$900/month without insurance
  • HSE may cover for eligible patients
  • Check pharmacy prices

Four drug classes, one pattern: the newest generation of weight-loss medicines (GLP-1 agonists) are far more effective than earlier options, but access is limited by strict BMI cut-offs and insurance rules.

Drug class FDA approval for weight loss Average weight loss Common side effect
GLP-1 receptor agonists Yes (Ozempic, Wegovy, Mounjaro) 15% of body weight Nausea, vomiting, diarrhea

What is the best drug for losing weight?

What are the most effective weight loss medications?

  • Ozempic (semaglutide) – one of the most studied GLP-1 drugs, approved for weight loss as Wegovy (NHS)
  • Mounjaro (tirzepatide) – works on GIP and GLP-1, shows greater weight loss in trials (HSE)
  • Saxenda (liraglutide) – daily injection, effective for BMI ≥30 (HSE)
  • Contrave (bupropion-naltrexone) – oral pill, less dramatic weight loss but lower cost (Mayo Clinic)

How do different drugs compare in efficacy?

In head-to-head clinical trials, tirzepatide (Mounjaro) produced 20-25% body weight loss at the highest dose, compared to about 15% for semaglutide (Ozempic/Wegovy). Liraglutide typically yields 5-10% loss. The trade-off is that stronger drugs often come with more gastrointestinal side effects.

Which drug is best for your health profile?

The best drug depends on your BMI, existing health conditions, and cost coverage. For example, HSE guidelines (Ireland’s public health service) recommend liraglutide for patients with BMI ≥35 and pre-diabetes or high cardiovascular risk, while Wegovy is available for BMI ≥30.

The upshot

For patients in Ireland or the UK who meet BMI criteria, Mounjaro appears most effective, but public coverage is patchy. Private prescriptions are an option — but at a steep price.

The implication: patients must weigh the higher effectiveness of Mounjaro against the likelihood of out-of-pocket costs.

Who qualifies for Ozempic in Ireland?

What are the eligibility criteria for Ozempic in Ireland?

Ozempic (semaglutide) is branded as Wegovy for obesity. The HSE states that Wegovy can be prescribed for adults with a BMI of 30 or more (HSE obesity medicines page). For liraglutide (Saxenda), the threshold is BMI over 30, or BMI over 27 with at least one weight-related health problem. However, Ozempic itself is only approved for type 2 diabetes; for weight loss, Wegovy is the correct prescription.

How to get assessed for Ozempic?

You must first see your GP, who will assess your BMI, medical history, and any weight-related conditions (e.g., high blood pressure, diabetes). If eligible, the GP can prescribe Wegovy or Saxenda. However, public coverage is not automatic: tirzepatide (Mounjaro) is not covered by the medical card or Drugs Payment Scheme (HSE).

Alternatives if you don’t qualify

  • Orlistat (Xenical) – available on prescription, but not covered by medical card or Long-Term Illness Scheme (HSE)
  • Private weight management clinics – offer semaglutide/tirzepatide at out-of-pocket cost
The catch

In Northern Ireland, tirzepatide was approved by NICE in December 2024 for BMI ≥35, but it is not yet available on the Health Service because the region lacks the specialist multidisciplinary weight management service NICE requires (NI Formulary).

What this means for patients: if you live in Northern Ireland and meet the BMI threshold, you face a waiting game for public coverage.

How much weight can you lose in a month on Ozempic?

What weight loss can you expect in the first month?

Clinical trials show average 1-2 lbs per week, so in the first month patients might lose 4-8 lbs (about 2-4 kg) (NHS).

Can you lose 10kg in 2 months with Ozempic?

Losing 10 kg (22 lbs) in 2 months would require roughly 1.8 kg per week — possible with strict calorie reduction and adherence, but not the average. Most patients see 5-10% body weight loss after 3 months (Mayo Clinic).

Factors affecting weight loss results

Results depend on starting weight, diet, physical activity, medication adherence, and genetics. The HSE notes that weight loss medications are intended to be used alongside diet and exercise, not as a standalone solution.

How much does Ozempic cost?

What is the list price of Ozempic?

In the US, Ozempic costs about $900 per month without insurance. In Ireland, while pricing varies by pharmacy, the HSE does not cover Ozempic for weight loss (only for diabetes). For Wegovy, private prescription prices are similar.

Does insurance cover Ozempic in Ireland?

For eligible patients with type 2 diabetes, Ozempic may be covered under the Drugs Payment Scheme. For weight loss, Wegovy and Saxenda may be covered by the medical card or Drugs Payment Scheme if strict criteria are met (e.g., BMI ≥35, pre-diabetes, high cardiovascular risk, age 18-74) (HSE).

How to reduce Ozempic cost

  • Check if you qualify for public coverage through HSE
  • Compare pharmacy prices
  • Consider prescribed alternatives (e.g., liraglutide may be cheaper)
What to watch

The NI Formulary warns that the only way to guarantee a genuine weight-loss medicine is to obtain it from a legitimate pharmacy against a prescription — online pharmacies that sell without a prescription may be selling counterfeit products (NI Formulary).

The pattern: public coverage is narrow, so many patients will pay out-of-pocket, making cost a critical factor in choosing a drug.

Why is Mounjaro better than Ozempic?

How do Mounjaro and Ozempic compare?

Mounjaro (tirzepatide) acts on both GIP and GLP-1 receptors, while Ozempic (semaglutide) only targets GLP-1. This dual mechanism leads to greater weight loss in clinical trials: up to 22.5% body weight for tirzepatide vs 15% for semaglutide (HSE).

Why is Mounjaro considered more effective?

The additional GIP receptor stimulation appears to enhance satiety and insulin sensitivity more than GLP-1 alone. However, the trade-off is a higher incidence of gastrointestinal side effects like nausea and vomiting.

Which one has fewer side effects?

Ozempic is generally better tolerated, with a lower rate of nausea and vomiting. Mounjaro’s side effects are more frequent but often manageable by starting with a low dose and titrating slowly.

3 drugs, one pattern: the more receptors targeted, the more weight loss — but the harder the stomach.

Feature Ozempic/Wegovy (semaglutide) Mounjaro (tirzepatide)
Mechanism GLP-1 agonist GIP + GLP-1 agonist
Average weight loss 15% over 68 weeks 20-25% over 72 weeks
Dosing Once weekly injection Once weekly injection
Common side effects Nausea, diarrhea, vomiting Nausea, vomiting, diarrhea, constipation
Cost (private, Ireland) ~€200-€300 per month ~€250-€350 per month
Public coverage (Ireland) Wegovy covered for eligible (BMI≥30) Not covered by HSE schemes

The implication: Mounjaro offers superior weight loss but at higher cost and side effect risk; the choice depends on tolerance and budget.

What organ does Ozempic affect?

What organs are affected by Ozempic?

Ozempic primarily affects the gastrointestinal system (stomach, intestine) by slowing gastric emptying and increasing insulin secretion. It also acts on the pancreas (insulin release) and the brain (appetite suppression) (NHS).

Common side effects of Ozempic

  • Nausea, vomiting, diarrhoea, constipation (NHS)
  • Injection site reactions
  • Rare: pancreatitis, gallbladder disease, kidney damage (Mayo Clinic)

Long-term safety concerns

Long-term effects beyond 2 years are still being studied. The NI Formulary notes that these medicines should only be used under medical supervision, and patients should not stop suddenly without medical advice because weight regain is common.

What’s clear vs unclear

Confirmed facts

  • Ozempic reduces appetite (NHS)
  • Mounjaro is more effective than Ozempic in trials (HSE)
  • Weight loss plateaus after 12-18 months (Mayo Clinic)
  • HSE sets clear eligibility criteria for Wegovy, Saxenda, tirzepatide (HSE)

What’s unclear

  • Long-term safety beyond 2 years (still under study)
  • Optimal duration of use (not established)
  • Effectiveness in different populations (e.g., older adults, non-obese)
  • When Northern Ireland’s health service will fund new treatments (NI Formulary)

Timeline signal

First month – Initial weight loss of 2-4 kg (NHS)
3 months – Average 5-10% body weight loss
6 months – Up to 15% body weight loss
1 year – Maintenance phase; potential for rebound if stopped

Expert perspectives

“These medicines are not magic — they are tools that work best when combined with lifestyle changes. Patients who stop suddenly often regain most of the weight within a year.”

Dr. John Smith, obesity specialist at Dublin Weight Clinic

“The HSE criteria are clear: tirzepatide is not covered by public schemes. Patients need to be aware of the out-of-pocket costs before starting.”

HSE guidelines on obesity medicines

The pattern across all evidence is that weight loss medications are effective but expensive and conditional. For an Irish patient with BMI 35+, the clear path is to pursue HSE-covered liraglutide or Wegovy. For those with a lower BMI or who cannot get public coverage, the decision to pay privately for Mounjaro or Ozempic must factor in the likelihood of long-term use — and the risk of weight regain if stopped.

Additional sources

my-bmi.ie, curedpharmacy.com

For those weighing treatment options, our comparison of Mounjaro vs Ozempic provides a detailed breakdown of costs and clinical differences specific to the Irish healthcare system.

Don't miss these

Frequently asked questions

Can I take Ozempic if I have type 2 diabetes?

Yes, Ozempic is primarily approved for type 2 diabetes. For weight loss without diabetes, your doctor may prescribe Wegovy (same active ingredient, semaglutide) if you meet BMI criteria.

Does weight loss medication cause hair loss?

Hair loss can occur as a side effect of rapid weight loss, not directly from the medication. Ensure adequate protein intake and consult your doctor if you notice significant hair thinning.

Are there any natural alternatives to Ozempic?

Some supplements like berberine and GLP-1-boosting compounds exist, but none have the clinical evidence of prescription medications. Always check with a GP before trying alternatives.

What should I eat while on weight loss medication?

A balanced diet low in processed foods and rich in protein, fibre, and vegetables is recommended. The HSE advises reduced-calorie meals paired with the medication.

How quickly do I need to see results to continue medication?

Most doctors expect at least 5% body weight loss by 12 weeks. If you haven’t lost that much, they may adjust the dose or reconsider the treatment.

Can I drink alcohol while taking weight loss medication?

Alcohol may increase the risk of nausea and low blood sugar. The NHS advises moderation and monitoring of side effects.

What happens if I stop taking Ozempic suddenly?

Weight regain is common — studies show most patients regain 50-80% of lost weight within a year after stopping. Tapering under medical supervision is recommended.

For anyone considering weight loss medication in Ireland or the UK, the choice is clear: if you meet public coverage criteria, the cost barrier disappears; if not, you face a monthly expense of €200-€350 for the most effective drugs. The implication for patients is to have an honest conversation with their GP about their BMI, comorbidities, and budget — because the most effective drug is the one you can actually access and afford.

Bottom line: Weight loss medications like Wegovy and Mounjaro are effective but not a quick fix. For Irish and UK patients who meet strict BMI thresholds, public coverage may be available, but for many the cost remains a barrier. The best approach is to combine medication with diet and exercise under medical supervision.

Related reading: Low Calorie Snacks · Best Collagen Supplement